GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ABBV-399 | ABBV399 | ABT-700-vcMMAE | Emrelis® | Teliso-V | telisotuzumab vedotin-tllv
telisotuzumab vedotin is an approved drug
Compound class:
Antibody
Comment: Telisotuzumab vedotin (ABBV-399; ABT-700) is an antibody-drug conjugate (ADC). It is a conjugate of the anti-hepatocyte growth factor receptor (HGFR; c-Met) antibody ABT-700 and the cytotoxic microtubule inhibitor MMAE (or vedotin) [3]. It was designed for anti-tumour activity in malignancies with MET amplification and/or c-Met overexpression, and that express constitutive c-Met signalling or ligand-dependent activation of c-Met.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| The FDA issued first approval for telisotuzumab vedotin in May 2025, to treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Phase 2 Interventional | AbbVie | ||
| NCT04928846 | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 Interventional | AbbVie | ||
| NCT06568939 | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 Interventional | AbbVie | ||
| NCT02099058 | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | Phase 1 Interventional | AbbVie | 1 | |
